Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
PRT-2527 by Prelude Therapeutics for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
PRT-2527 by Prelude Therapeutics for Non-Small Cell Lung Cancer: Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PRT-2527 by Prelude Therapeutics for Solid Tumor: Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
PRT-2527 by Prelude Therapeutics for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia): Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic...
PRT-2527 by Prelude Therapeutics for Sarcomas: Likelihood of Approval
PRT-2527 is under clinical development by Prelude Therapeutics and currently in Phase I for Sarcomas. According to GlobalData, Phase I...